Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼º»ó¼¼Æ÷Á¾ÀÇ MIB-1, AgNORs ¹× PCNA ¹ßÇö¿¡ ´ëÇÑ ºñ±³¿¬±¸ A Comparative Study on MIB-1, AgNORs and PCNA Expressions in Astrocytic Tumors

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1997³â 26±Ç 4È£ p.476 ~ 485
¼Ò¼Ó »ó¼¼Á¤º¸
Ã־繮/Yang Moon Choi ±èÅ¿µ/±èÁ¾¹®/À±±âÁß/¹®Çü¹è/Tae Young Kim/Jong Moon Kim/Ki Jung Yoon/Hyung Bae Moon

Abstract

°á ·Ð
¼º»ó¼¼Æ÷Á¾ 28¿¹¸¦ ´ë»óÀ¸·Î Áõ½Ä °è¼öÀÎ MIB-1Ç¥ÁöÁö¼ö, AgNORs count, PCNA Ç¥ÁöÁö
¼ö¸¦ ÃøÁ¤ÇÏ¿© ºñ±³ ºÐ¼®ÇÑ °á°ú ´ÙÀ½°ú °°Àº °á·ÐÀ» ¾ò¾ú´Ù.
1) MIB-1 Ç¥ÁöÁö¼ö´Â ¾ç¼º ¼º»ó¼¼Æ÷Á¾ 3¡¾1.91%, ¿ªÇü¼º ¼º»ó¼¼Æ÷Á¾ 7¡¾3.745, ±³¾Æ¼¼Æ÷
Á¾ 10¡¾7.58%·Î ¾Ç¼ºµµ°¡ ³ôÀ»¼ö·Ï ³ô¾ÒÀ¸¸ç, ±³¾Æ¼¼Æ÷Á¾±º°ú ¾ç¼º¼º»ó¼¼Æ÷Á¾±º »çÀÌ, ¿ªÇü
¼º ¼º»ó¼¼Æ÷Á¾±º°ú ¾ç¼º¼º»ó¼¼Æ÷Á¾±º »çÀÌ¿¡¼­´Â Á¶Á÷ÇÐÀû ¾Ç¼ºµµ¿Í MIB-1 Ç¥ÁöÁö¼ö »çÀÌ
¿¡ Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ »ó°ü°ü°è°¡ ÀÖ¾ú´Ù.(p<0.005).
2) AgNORs ¼ö´Â ¾ç¼º ¼º»ó¼¼Æ÷Á¾ 1.28¡¾0.26°³, ¿ªÇü¼º ¼º»ó¼¼Æ÷Á¾ 1.99¡¾0.64°³, ±³¾Æ¼¼
Æ÷Á¾ 1.96¡¾0.57°³·Î ±³¾Æ¼¼Æ÷Á¾°ú ¾ç¼º ¼º»ó¼¼Æ÷Á¾±º »çÀÌ (p<0.001)¿Í ¿ªÇü¼º ¼º»ó¼¼Æ÷Á¾
±º°ú ¾ç¼º ¼º»ó¼¼Æ÷Á¾±º »çÀÌ(p<0.01)¿¡´Â ÇüÅÂÇÐÀû ¾Ç¼ºµµ¿Í AgNORs »çÀÌ¿¡ Åë°èÇÐÀûÀ¸
·Î À¯ÀÇÇÑ »ó°ü°ü°è°¡ ÀÖ¾ú´Ù.
3) PCNA Ç¥ÁöÁö¼ö´Â ¾ç¼º¼º»ó¼¼Æ÷Á¾ 7.1¡¾2.67%, ¿ªÇü¼º ¼º»ó¼¼Æ÷Á¾ 11.6¡¾5.24%, ±³¾Æ
¼¼Æ÷Á¾ 24.5¡¾10.39%·Î ¾Ç¼ºµµ ³ôÀ»¼ö·Ï ³ô¾ÒÀ¸¸ç, ±³¾Æ¼¼Æ÷Á¾±º°ú ¿ªÇü¼º ¼º»ó¼¼Æ÷Á¾±º »ç
ÀÌ, ±³¾Æ¼¼Æ÷Á¾±º°ú ¾ç¼º ¼º»ó¼¼Æ÷Á¾±º »çÀÌ¿¡¼­´Â Á¶Á÷ÇÐÀû ¾Ç¼ºµµ¿Í PCNA Ç¥ÁöÁö¼ö »ç
ÀÌ¿¡ Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ »ó°ü°ü°è°¡ ÀÖ¾ú´Ù.(p<0.05).
4) ¼±»óȸ±ÍºÐ¼®»ó MIB-1 Ç¥ÁöÁö¼ö, AgNORs ¼ö, PCNA Ç¥ÁöÁö¼ö »óÈ£°£¿¡ Åë°èÇÐÀû ÀÇ
¹Ì ÀÖ´Â °ü°è¸¦ º¸¿© ÁÖ¾ú´Ù.(p<0.05).
ÀÌ¿Í °°Àº °á°ú¸¦ Á¾ÇÕÇÏ¿© º¼ ¶§, MIB-1À̳ª AgNORs Áõ½ÄÁö¼öµéÀº ¼º»ó¼¼Æ÷Á¾¿¡¼­ Á¶
Á÷ÇÐÀû ¼Ò°ß°ú ´õºÒ¾î Á¾¾ç¼¼Æ÷ÀÇ ºÐ¿­´É·ÂÀ» ÃßÁ¤Çϴµ¥ À¯¿ëÇÏ°Ô »ç¿ëµÉ ¼ö ÀÖÀ½À» ½Ã»ç
ÇÏ¿´À¸¸ç, À̸¦ Âü°íÇÔÀ¸·Î½á ȯÀÚÀÇ ¿¹ÈÄ ÃøÁ¤À̳ª Ä¡·á ¹æ¹ýÀÇ ¼±Åÿ¡ µµ¿òÀ» ¾òÀ» ¼ö ÀÖ
À» °ÍÀ¸·Î »ç·áµÇ¾ú´Ù. ¶ÇÇÑ ¿¹ÈÄ¿ÍÀÇ °ü°è¸¦ ÃßÁ¤Çϱâ À§Çؼ­´Â ¸¹Àº ´ë»óÀÇ È¯Àڵ鿡¼­
ÀÌ·¯ÇÑ ¿¬±¸¸¦ ½ÃÇàÇÔÀ¸·Î½á ±× Á߿伺À» È®ÀÎÇؾ߸¸ ÇÒ °ÍÀ¸·Î ÆǴܵȴÙ.
#ÃÊ·Ï#
Cell cycle associated nuclear proteins such as proliferating cell nuclear antigen(PCNA),
argyrophilic nucleolar organizer regions(AgNORs) and the family of nuclear proteins
identified by the Ki-67 epitope, have been primarily utilized for estimating of growth
potential of neoplasms. Although PCNA and AgNORs staining are possible in the
paraffin-embedded tissue, Ki-67 staining had been only possible on frozen sections,
Recently monclonal antibody MIB-1 is available, and reacts with the Ki-67 epitope in
paraffin-embedded tissue.
Twenty eight astrocytic tumors in paraffin-embedded, archival materials were stained
by immunohistochemical technique for the MIB-1, PCNA, and by silver colloid stain for
AgNORs. The MIB-1 labeling indicies(LI) ranged from 2 to 25%(10¡¾7.58) for 10
glioblastomas ; form 2 to 15%(7¡¾3.74) for 11 anaplastic astrocytomas ; and form 1 to
5%(3¡¾1.91) for low grade astrocytomas. Glioblastoma and anaplastic astrocytomas
exhibited significantly higher MIB-1 LI than their benign counterparts(p<0.05)
The AgNORs count per cell ranged from 1.3 to 3.1(1.96¡¾0.57) for 10 glioblastomas ;
from 1.2 to 3.1(1.9¡¾0.64) for 11 anaplastic astrocytomas : and from 0.8 to 1.5(1.2¡¾0.26)
for low grade astrocytomas. Glioblastomas and anaplastic astrocytomas exhibited
significantly higher AgNNORs count than their benign counterparts(p<0.05).
The PCNA LI ranged form 10 to 40%(24.5¡¾10.39) for 10 glioblastomas ; from 5 to
20%(11.6¡¾5.24) for 11 anaplastic astrocytomas ; and from 5 to 10%(7.1¡¾2.67) for low
grade astrocytomas. The differences of PCNA LI between glioblastomas and anaplastic
astrocytomas(p<0.01), and between glioblatomas and low grade astrocytomas(p<0.001)
were statistically significant.
Linear regression analysis showed correlations between MIB-1 and AgNORs
count(Spearmans r=0.4306, p<0.05) between PCNA LI and AgNORs count(Spearmans's
r=0.586, p<0.05) and between PCNA and MIB-1 LI(Spearman's r=0.4523, p<0.05).0
These findings suggest that LI of MIB-1, PCNA and AgNORs count are correlated
each other, and can be used as helpful markers for differentiating astrocytic tumors in
addition to conventional staining methods.

Å°¿öµå

Astrocytoma; MIB-1; AgNORs; PCNA; Growth potential.;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS